Lilly partners with NIH for rare-disease research

Share this article:

Although small biotechs are often associated with rare-disease research, a recent announcement by the National Institutes of Health has officially roped in the bigger players. The government organization has partnered with Eli Lilly to develop a long-acting parathyroid hormone analog for hypoparathyroidism, a condition in which the body produces too little parathormone.

The NIH's Therapeutics for Rare and Neglected Diseases is kicking in money for the study, which is part of a wider announcement that includes two other rare-disease conditions that are being explored: LEOPARD syndrome, which is associated with a rare cardiac disorder, and retinitis pigmentosa, a severe form of hereditary blindness.

NIH notes in its announcement that private companies generally avoid small-population diseases because the return on investment is expected to be poor. This is despite some surface incentives, such as smaller clinical trials and prescription prices that can be in the hundreds of thousands. The NIH said in the announcement that efforts like funding research through the Therapeutics for Rare and Neglected Disease programs are meant to help de-risk exploration and “make possible new drugs more commercially viable and attractive to outside partners.”

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...